Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 110, Issue 2, Pages 209-212Publisher
WILEY
DOI: 10.1111/ejh.13881
Keywords
BTK; COVID-19; innate immunity; monocytes; SARS-CoV-2; X-linked agammaglobulinemia
Categories
Ask authors/readers for more resources
An XLA patient with a 7-month course of COVID-19 showed persistent plasma SARS-CoV-2 load. The myeloid cells exhibited a sustained non-inflammatory profile, which was associated with contained severity of the disease. This suggests the potential benefit of using BTK inhibitors in SARS-CoV-2 infection.
XLA patient with 7-month course of COVID-19 with persistent plasma SARS-CoV-2 load revealed a sustained non-inflammatory profile of myeloid cells in association with contained severity of disease, arguing in favor of the use of BTK inhibitors in SARS-COV-2 infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available